Objective
Kaposi’s Sarcoma-associated herpesvirus, or human herpesvirus 8, is an important cause of morbidity and mortality, causing tumors in immunosuppressed patients, in particular those with AIDS. Like other herpesviruses, KSHV has evolved numerous mechanisms of escape from both the innate and adaptive host immune response. These immune evasion strategies facilitate the virus’s oncogenic potential and contribute to its pathogenesis. Beyond immune modulation, many viral proteins interact with components of the cellular proteome to enable viral replication. However, the complete array of such proteins, their kinetics and fate in both latent and lytic phase of viral infection has never been determined. Here, I propose an unbiased proteomic approach to analyze the expression kinetics of the KSHV proteome in the context of cellular infection, and explore how host cell surface and cytoplasmic proteins are regulated by this virus throughout its infection cycle. To achieve this goal I will resolve both the host cell and the viral proteome in primary endothelial cells and B cells using the recently developed technique, quantitative temporal viromics. This novel approach is interdisciplinary, incorporating virology, immunology, cell biology, state-of-the-art proteomics and has been successfully applied to identify novel markers of latent HCMV infection as well as novel immunomodulation strategies. The proposed study will allow a temporal analysis of how the host and viral proteome change upon latent as well as lytic KSHV infection. Newly discovered viral targets, such as ligands for Natural killer (NK) or cytotoxic T cells will be validated and investigated using biochemical and virological methods available in the host (Lehner) lab. The results of this study will therefore provide unique insight into the virus-host interactions and uncover novel viral strategies of the host immune system. The identified proteins may ultimately serve as novel targets for therapeutic interventions.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins proteomics
- natural sciences biological sciences microbiology virology
- medical and health sciences basic medicine immunology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2014
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
CB2 1TN CAMBRIDGE
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.